{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:07:29Z","timestamp":1788887249971,"version":"build-2803163510"},"reference-count":14,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    CD19\u2010directed chimeric antigen receptor (CAR) T\u2010cell therapy has transformed outcomes for patients with relapsed or refractory (r\/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR\u2010T surveillance and consolidation strategies. Measurable residual disease (MRD) has emerged as a powerful prognostic biomarker in frontline MCL, but its role after CAR T\u2010cell therapy remains incompletely defined. We retrospectively analyzed 37 patients with r\/r MCL treated with brexucabtagene autoleucel (brexu\u2010cel). MRD was assessed using next\u2010generation immunoglobulin high\u2010throughput sequencing (Ig\u2010HTS) of peripheral blood mononuclear cells obtained before lymphodepletion, at 1\u2010 and 3\u2010months post\u2010infusion, and every 3\u2009months thereafter. Clonotype identification was successful in 36 of 37 patients. Pre\u2010lymphodepletion MRD levels were lower in patients receiving bridging therapy (337 [0\u2013198\u2009449] vs. 21\u2009213 [1\u2013788\u2009251];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04), and MRD undetectability trended toward improved progression\u2010free survival (PFS; unreached vs. 28.5\u2009months; HR 5.2;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.07). Post\u2010infusion, patients with detectable Day 28 MRD had inferior PFS compared with those with undetectable MRD (10.9 vs. 51.5\u2009months; HR 3.99;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002), whereas Day 28 PET\u2010CT response did not correlate with PFS (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.35; HR 1.8). Longitudinal MRD monitoring identified relapse a median of 6.5\u2009months before PET\/CT in most relapsing patients (15 out of 18). Early and serial MRD monitoring is thus a sensitive prognostic and surveillance tool in brexu\u2010cel treated MCL, with Day 28 MRD serving as an early predictor of long\u2010term outcomes.\n                  <\/jats:p>","DOI":"10.1002\/ajh.70343","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:01:21Z","timestamp":1777888881000},"page":"1818-1827","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post\n                    <scp>CAR<\/scp>\n                    \u2010T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse"],"prefix":"10.1002","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0845-1474","authenticated-orcid":false,"given":"Snegha","family":"Ananth","sequence":"first","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University  Stanford California USA"},{"name":"University of Nebraska Medical\u00a0Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Sahaf","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7332-5146","authenticated-orcid":false,"given":"Allison","family":"Jacob","sequence":"additional","affiliation":[{"name":"Adaptive Biotechnologies  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lik Wee","family":"Lee","sequence":"additional","affiliation":[{"name":"Adaptive Biotechnologies  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Simmons","sequence":"additional","affiliation":[{"name":"Adaptive Biotechnologies  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Kirsch","sequence":"additional","affiliation":[{"name":"Adaptive Biotechnologies  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen\u2010kai","family":"Weng","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Miklos","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02214"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01797"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.06.011"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.51959"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00961-8"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001077"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-212973"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07077-9"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00377"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006397"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01710-w"},{"issue":"472","key":"e_1_2_12_14_1","first-page":"e1","article-title":"Cell\u2010Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression After Chimeric Antigen Receptor T Cell Therapy in Patients With Diffuse Large B Cell Lymphoma","volume":"29","author":"Bastos\u2010Oreiro M.","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011997"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70343","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70343","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:16:46Z","timestamp":1788884206000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/ajh.70343"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70343","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"2026-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}